未登录

Z

Zefeng Xu

chinese academy of medical sciences - peking union medical college

H指数:36

被引数:5,008

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms

骨髓增生异常综合征/肿瘤中无效性红细胞生成和信号通路失调的相关性

hematology oncology

IF13.5

2025-05-140

OA

GATA1 insufficiencies in dysmegakaryopoiesis of myelodysplastic syndromes/neoplasms

MDS/MPN中异常巨核细胞生成的GATA1不足

PATHOLOGY RESEARCH AND PRACTICE

IF3.2

2025-05-010

PRE

GATAI Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

GATAI 在骨髓增生异常综合征/肿瘤中的巨核细胞发育异常不足

IF23.1

2024-11-050

PRE

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression

BLOOD CANCER JOURNAL

IF11.6

2023-04-203

OAAI

Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis

ANNALS OF MEDICINE

IF4.3

2023-01-163

OAAI

Distinguishing myelodysplastic syndromes with moderate-to-severe bone marrow fibrosis from triple-negative primary myelofibrosis based on clinical and genetic covariates

HEMATOLOGICAL ONCOLOGY

IF3.9

2022-10-270

PRE

IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes

hematology oncology

IF13.5

2022-10-1720

OAAI

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms

IF13.4

2022-10-1225

OAAI

ASXL1 mutations accelerate bone marrow fibrosis via EGR1-TNFA axis-mediated neoplastic fibrocyte generation in myeloproliferative neoplasms

IF7.9

2022-08-2512

OAAI

Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study

HEMATOLOGICAL ONCOLOGY

IF3.9

2022-05-288

PRE

Conventional interferon-α 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center

IF7.9

2022-01-066

OAAI

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera

BLOOD CANCER JOURNAL

IF11.6

2021-09-177

OAAI

RBC distribution width predicts thrombosis risk in polycythemia vera

IF13.4

2021-09-0811

OAAI

Is race important in genomic classification of hematological neoplasms?

HEMATOLOGICAL ONCOLOGY

IF3.9

2021-08-143

PREAI

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder

伴有自身免疫性疾病的骨髓增生异常综合征中的VEXAS综合征

hematology oncology

IF13.5

2021-03-1951

OAAI

Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk

ANNALS OF ONCOLOGY

IF65.4

2020-09-010

OAAI

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre

BLOOD CANCER JOURNAL

IF11.6

2020-08-143

OAAI

SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints

IF13.4

2019-04-0934

OAAI

Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes

CANCER DISCOVERY

IF33.3

2018-11-0141

OAAI

Hayashi, Yoshihiro; Zhang, Yue; Yokota, Asumi; Yan, Xiaomei; Liu, Jinqin; Choi, Kwangmin; Li, Bing; Sashida, Goro; Peng, Yanyan; Xu, Zefeng; Huang, Rui; Zhang, Lulu; Freudiger, George M.; Wang, Jingya; Dong, Yunzhu; Zhou, Yile; Wang, Jieyu; Wu, Lingyun; Bu, Jiachen; Chen, Aili; Zhao, Xinghui; Sun, Xiujuan; Chetal, Kashish; Olsson, Andre; Watanabe, Miki; Romick-Rosendale, Lindsey E.; Harada, Hironori; Shih, Lee-Yung; Tse, William; Bridges, James P.; Caligiuri, Michael A.; Huang, Taosheng; Zheng, Yi; Witte, David P.; Wang, Qian-Fei; Qu, Cheng-Kui; Salomonis, Nathan; Grimes, H. Leighton; Nimer, Stephen D.; Xiao, Zhijian; Huang, Gang

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response

BLOOD CANCER JOURNAL

IF11.6

2018-01-1530

OAAI